HCID 71280109, compound → HCID 71279865, compound

Participants

Reaction Steps

N-(4-(tert-butyldimethylsilyloxy)-2-methylbutan-2-yl)-2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (70 mg, 0.140 mmol) was dissolved in 30 mL of a saturated solution of HCl (g) in dioxane and the solution was stirred at room temperature for one hour. The solvent was evaporated at 40° C. under reduced pressure and the residue was purified by preparative-HPLC (Gemini 5u C18 150×21.2 mm; inject volume: 3 mL/inj, flow rate: 20 mL/min; wavelength: 214 nm and 254 nm; the gradient conditions were: 38% acetonitrile/62% water (0.1% trifluoroacetic acid, v/v) initially, proceeding to 42% acetonitrile/58% water (0.1% trifluoroacetic acid, v/v) in a linear fashion over 9 min.) to give 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-N-(4-hydroxy-2-methylbutan-2-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (15 mg, 27.6%) as a yellow solid. MS: (M+H)+=397; 1H NMR (300 MHz, DMSO): δ 12.84 (s, 1H), 9.10 (s, 1H), 8.55-8.50 (m, 1H), 8.40 (s, 1H), 7.89 (s, 1H), 7.73-7.69 (m, 1H), 7.22-7.16 (m, 1H), 7.42 (t, 2H, J=4.6 Hz), 4.17 (s, 3H), 3.61-3.55 (m, 2H), 2.13-2.09 (m, 2H), 1.25 (s, 6H).

Provenance & Evidence